Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2002

View Archived Issues

Gruenenthal patents novel opioid analgesics

Novel factor Xa inhibitors claimed by Merck KGaA

BMS presents new polycyclic DNA topoisomerase I inhibitors

Sankyo describes Th1-selective immunosuppressants

PPARgamma ligands for use in obesity, bone diseases, lipoprotein disorders, etc.

GSK claims Lp-PLA2 inhibitors for use in atherosclerosis

The NMDA receptor antagonist LY-235959 attenuates cocaine conditioning in rats

Dopamine uptake inhibitors and the attenuation of cocaine selfadministration

Selegiline enhances smoking cessation rates among nicotine-dependent smokers

Barr completes acquisition of Enhance assets

Roche and Genmab expand antibody collaboration

Pfizer returns pagoclone rights to Indevus

Dusa to reacquire rights to Levulan PDT from Schering AG

Pharmos receives grant to fund development of dexanabinol for traumatic brain injury

Hemosol revises timetable for Hemolink

NIDA and Britannia stop phase III trials of first nonopiate detoxification agent

Minocycline effective in an experimental model of amyotrophic lateral sclerosis (ALS)

Oral streptogramin shows promise for community-acquired infections

NU:UB-73 exerts antitumor activity via an unidentified metabolite

Antitumor activity of J-103 involves Fas/FasL system

Successful in vivo gene therapy of Gaucher's disease discussed at ASGT meeting

Merck & Co. revises Zocor prescribing information

AstraZeneca and Pierre Fabre team up to evaluate Iressa in combination with vinorelbine in NSCLC

Preliminary data for Angiozyme in combination with chemotherapy in metastatic colorectal cancer

Shire files for approval of Fosrenol in Canada

Fujisawa to market Zindaclin in continental Europe

CX-516 shows promising results in Alzheimer's disease

Anadys and Gilead collaborate on novel antiviral compound discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...